医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZRG Partners Life Sciences Hiring Index Shows Modest Gains in 4th Quarter

2014年02月07日 AM01:25
このエントリーをはてなブックマークに追加


 

WEST ORANGE, N.J.

ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index. Q4 reflects an overall gain in hiring, with Pharma activity over the long term reaching an all-time index high. Meanwhile R&D hiring took a hit dropping 15% from the previous quarter. The Asia Pacific Region saw significant hiring in Q4, more than 25%, with most being attributed to the Sales and Marketing function.

ZRG Managing Director David Fortier commented, “The results of this latest index correlate with the broader economy – inconsistencies across regions, sectors, and functions along with the continuation of a longer term trend of slow, steady, but uneven growth. The positive to take from these numbers is some robust hiring in selected functions within pharmaceuticals and a return of hiring in the commercial function indicating expectations of growth for some companies.”

About ZRG Partners

ZRG Partners, Inc. is a global authority on talent management issues in the Life Sciences, Pharmaceutical and Medical markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions.

The Global Life Sciences Hiring Index analysis utilizes a proprietary algorithm that looks at confidential hiring within selected benchmark companies in three distinct segments. The companies in the Index generate over $634 billion in revenues and employ over 1,300,000 people globally. ZRG Partners conducts extensive direct market research in developing the data that drives the Index.

For more information about ZRG please go to www.zrgpartners.com

CONTACT

ZRG Partners
Adam
El Din
, +41-22-319-3304
European President and Global Practice
Head of Life Sciences
or
David
Fortier
, +1-202-525-1341
Managing Director

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc